Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (313 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-01-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: resistanttherapyto assessto randomizationpregnancy
  Phrases that lowered it: clinicalefficacytreatment ofequalcriteria patients
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Maximum age: 99 (lowers risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 93.1% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 18% (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 214 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia NCT01515020 · started 2012 · scored riskier than 64% of active trials terminated
• Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia NCT00695903 · started 2008 · scored riskier than 59% of active trials terminated
• Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia NCT01975662 · started 2014 · scored riskier than 64% of active trials terminated
• Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia NCT03138733 · started 2018 · scored riskier than 89% of active trials completed
• A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia NCT05225558 · started 2022 · scored riskier than 18% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.